Fig. 1 · Structure

Documents & Downloads

NOD-IN-1

Cat. No. A13171 CAS 132819-92-2

NOD-like receptors inhibitor

NOD-IN-1 is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors, NOD1 and NOD2, with IC50 of 5.74 μM and 6.45 μM, respectively.

In Stock

Publications for NOD-IN-1

1 publication citing this product

  1. Shuqin Lai, .et al. , Int Immunopharmacol, 2025, Feb 6:147:114036 PMID: 39778279

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

NOD-IN-1 Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of NOD-IN-1 from 2 published references. In vitro models include A549 and H1299 human lung adenocarcinoma cells.

NOD-IN-1 In Vitro Studies

In a separate inhibitor comparison in A549 and H1299 lung adenocarcinoma cells, the displayed western blots did not show a marked reduction in vimentin or vimentin-K104 acetylation with 10 µM NOD-IN-1. This qualitative observation limits extrapolation to these readouts; it does not establish a statistical null effect. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Qualitative limiting result in lung adenocarcinoma cell lines

Cell-based study · A549 and H1299 human lung adenocarcinoma cells [1]

In the representative western blots, the NOD-IN-1 lanes retained vimentin and acetylated vimentin-K104 signals relative to DMSO, without the marked reduction seen with MCC950. This is a qualitative comparison; no quantified NOD-IN-1 effect size or statistical null result is established.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Vimentin and vimentin-K104Ac protein signals, with GAPDH loading controlQualitative western blot comparison No marked reduction apparent in the NOD-IN-1 lanes relative to DMSO in the displayed A549 and H1299 blots; no numerical effect or P value adopted.[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Method
Cell treatment followed by western blotting
Vehicle
DMSO control
Co-treatment
NOD-IN-1 tested separately from MCC950, CY-09 and Nodinitib-1; no combination efficacy claim.
Reported limits
Duration labels are not reliably legible in the retained small Figure 7 image; no duration claim is adopted. A numerical NOD-IN-1-specific effect and its statistical significance are not established by the reviewed panel.
Methods and source locations

Compound reported in the paper: NOD-IN-1; Compound label in the paper: NOD-IN-1, separate inhibitor comparison arm

A model-specific qualitative limiting observation, not proof of NOD1/NOD2 inactivity or NLRP11 target engagement.

Results 2.7; Figure 7B–C and caption; Experimental Section: Plasmids and Reagents, Cell Lines and Culture, Western Blot Analysis

Vimentin and vimentin-K104Ac protein signals, with GAPDH loading control: Western blot; Figure 7B (A549) and 7C (H1299). MCC950, CY-09 and Nodinitib-1 are separate comparison treatments. — Results 2.7; Figure 7B–C and caption; Experimental Section: Plasmids and Reagents, Cell Lines and Culture, Western Blot Analysis

NOD-IN-1 In Vivo Studies

In a male C57BL/6 mouse model of osteoarthritis induced by meniscal destabilization, local NOD-IN-1 treatment reduced the cartilage histology damage score compared with vehicle. This model-specific result does not distinguish the contributions of NOD1 and NOD2 inhibition. [2]

NOD-IN-1 reduced cartilage damage in a surgical mouse osteoarthritis model

Animal study · Male C57BL/6 mice, 12 weeks old; destabilization of the medial meniscus (DMM) [2]

The NOD-IN-1 arm had a lower OARSI cartilage histology score than the DMM vehicle arm. Sham plus vehicle and a separate GSK717 comparator were also included. The result is specific to local treatment in this mouse model; it does not isolate NOD1 from NOD2 inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cartilage degradation scored on Safranin O/Fast Green sections; sum of four anatomical quadrants, total range 0–24OARSI score 7.00 ± 3.23 (NOD-IN-1) versus 14.50 ± 3.45 (DMM vehicle); mean ± SD; n = 6 mice/group; P = 0.0019[2]

Conditions shared by the study groups

Route
Intraarticular
Frequency
Twice a week
Treatment course
7 weeks, beginning 1 week after DMM
Vehicle
2% DMSO plus 98% saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
DMM + NOD-IN-1
1 mM solution; injection volume unspecified
DMM + vehicle; sham + vehicle provided a surgical baseline; GSK717 was a separate comparator.OARSI score 7.00 ± 3.23 versus 14.50 ± 3.45 with DMM vehicle (mean ± SD; n = 6 mice/group; P = 0.0019).[2]
DMM + NOD-IN-1
Model: Male C57BL/6 mice, 12 weeks old at model induction
Reported limits: No inhibitor injection volume or NOD-IN-1 supplier/lot is specified in the reviewed original methods.
Methods and source locations

Compound reported in the paper: NOD-IN-1; Compound label in the paper: NOD-IN-1

Research observation for the named compound in a local mouse joint treatment model; no clinical efficacy or Adooq lot claim.

Results: NOD2 is a potential therapeutic target for OA; Figure 8K–L and caption; Methods: Animal models of OA (NOD2 inhibitor injection experiment), Histological staining and analysis

Cartilage degradation scored on Safranin O/Fast Green sections; sum of four anatomical quadrants, total range 0–24: Histological OARSI scoring. Figure 8L specifies one-way ANOVA with Tukey’s multiple-comparison test. — Results: NOD2 is a potential therapeutic target for OA; Figure 8K–L and caption; Methods: Animal models of OA (NOD2 inhibitor injection experiment), Histological staining and analysis

DMM + NOD-IN-1 · Results: NOD2 is a potential therapeutic target for OA; Figure 8K–L and caption; Methods: Animal models of OA (NOD2 inhibitor injection experiment), Histological staining and analysis

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 132819-92-2
Applications NOD-like receptors inhibitor
Formula C18H17NO4S
Molecular Weight 343.4
SMILES
O=S(N1C(C(OCC)=O)=CC2=CC=CC=C21)(C3=CC=C(C)C=C3)=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 63 mg/mL (183.46 mM)
Water Insoluble
Ethanol 5 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

NOD-IN-1 Research References

  1. [1] Rui Yang, Weilin Peng, Shuai Shi, et al. The NLRP11 Protein Bridges the Histone Lysine Acetyltransferase KAT7 to Acetylate Vimentin in the Early Stage of Lung Adenocarcinoma Advanced Science (2023). PMID: 37424170 DOI: 10.1002/advs.202300971 Source material
  2. [2] Yuting Wang, Song Li, Yonghui Dong, et al. Innate immune sensor NOD2 promotes cartilage degradation and osteoarthritis progression by stabilizing TRAF6 in chondrocytes JCI Insight (2026). PMID: 42635041 DOI: 10.1172/jci.insight.196750 Source material

Publications

1 publication citing this product

  1. Shuqin Lai, .et al. , Int Immunopharmacol, 2025, Feb 6:147:114036 PMID: 39778279

Added to your cart

View Cart Checkout
Loading...